Answers are grounded in this paper and cite their sources.
Invasive fungal infections (IFIs) remain a major global health threat, particularly among immunocompromised patients. Current antifungals that target ergosterol biosynthesis, cell-wall assembly, and nucleic-acid synthesis are increasingly constrained by toxicity, drug-drug interactions, suboptimal pharmacokinetics, narrow spectra, and rising resistance. This review provides the transition from conventional antifungal agents to a next-generation, precision-oriented therapeutic landscape. In Part I, we expand the antifungal target repertoire beyond classical pathways to include emerging molecular nodes. Part II outlines principles for precision antifungal therapeutics, distinguishing pathogen-specific from broad-spectrum approaches and species-tailored regimens, and integrates rapid diagnostics into companion diagnostic frameworks. Part III surveys advanced therapeutic platforms, encompassing antifungal peptides, antibody-based agents, nucleic acid therapeutics, and engineered probiotic strategies. Part IV highlights drug-delivery innovations, including liposomal and nanoparticle carriers, stimuli-responsive systems, antibody- and ligand-targeted constructs, formulations optimized for biofilm penetration and intracellular delivery, and phage-inspired delivery, with AI-assisted design accelerating formulation optimization. Part V synthesizes combination strategies. Together, these advances define a conceptual framework for precision antifungal medicine that integrates pathogen profiling, host factors, pharmacogenomics, therapeutic drug monitoring, and multi-omics data to individualize therapy, overcome resistance, improve selectivity, and enhance clinical outcomes in IFIs.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: